Wolfgang M.
- Country
- Germany
- Department
- ZIM Med II
Research Overview
- Pharmacokinetic Evaluation of Efanesoctocog Alfa Versus Other Extended Half-Life Recombinant Factor VIII Products in Severe Haemophilia A Patients
- Phase III Randomized Open‑Label Trial of Subcutaneous NXT007 Prophylaxis versus Intravenous Factor VIII Prophylaxis in Patients with Hemophilia A without Inhibitors
- Phase 3 Multicenter Randomized Open‑Label Trial of Efanesoctocog Alfa Intensified Replacement Therapy for Synovitis in Patients with Congenital Hemophilia A
Data & Insights
Has run more than one trial at 44 of 132 partner sites.
Specializations
Bleeding Disorders Management
The investigator specializes in treating severe hemophilia A and B, with particular focus on developing innovative therapeutic approaches for patients with these conditions.
- Factor VIII replacement therapy
- Gene therapy approaches for hemophilia
- Novel prophylactic treatments
Research activities encompass both traditional factor replacement and advanced therapeutic strategies.
Immune System Disorders
Expertise in treating chronic immune thrombocytopenia (ITP), focusing on immunoglobulin-based therapies and platelet response assessment.
- Intravenous immunoglobulin treatment
- Platelet count management
- Long-term disease control strategies
Specializes in developing treatment protocols for adult patients with chronic ITP.
Advanced Therapeutics
Focuses on evaluating novel therapeutic approaches including gene therapy vectors and recombinant proteins for inherited blood disorders.
- AAV-based gene therapy
- Long-acting factor replacements
- Subcutaneous treatment options
Investigates innovative delivery systems and treatment modalities for improved patient outcomes.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.